Fate Therapeutics, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
5.4
Bearish
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
FATE
Clean balance sheet with low leverage (0.4× debt-to-equity).
⚠ low return on equity (-52%).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
HOLD
Target $5.19 (+239.1%)
8 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
FATE
PFE
—
Trailing P/E
19.4×
-1.5×
Forward P/E
9.4×
0.0%
Profit Margin
12.4%
0.0%
Gross Margin
75.8%
-51.8%
ROE
8.9%
-26.4%
Revenue Growth
-1.2%
—
Earnings Growth
—
2.24
Beta
0.39
—
Price / Book
—
$178M
Market Cap
$149.8B
$1 – $2
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →